Evaluate higher DAR needed for targeting tumor cells with low antigen expression
Explore the development of high-DAR ADCs using novel expression systems and precise conjugation
Utilize dual conjugation to maximize ADC potency
9:30 am DEP Dendrimers as a Versatile Platform for Design of Customized Targeted Drug Conjugates – Linker & Conjugation Strategies
Jeremy PaullVice President - Development and Regulatory Affairs, Starpharma Ltd.
Synopsis
Discussing Starpharma’s polylysine DEP® dendrimers as an ideal platform for targeted drug conjugates to promote hydrophilicity, reduce aggregation and minimize conjugation sites whilst achieving high DARs
Highlighting the utility and flexibility of the DEP® dendrimer platform for a wide range of linker and conjugation strategies for the design of targeted dendrimer drug conjugates (DDCs) for precision therapies
Reviewing results achieved to date with Starpharma’s HER2-targeted and other DDCs
10:00 am Leveraging Linker Design & Drug Developability Assessment to Develop Successful ADCs
Synopsis
Explore how ADC linkers represent more than a bridge between the antibody and payload, allowing to modulate ADCs’ biological activity
Discuss how identifying the best combination of antibody, linker and payload is a challenge that can be overcome by applying stage-specific evaluation criteria to de-risk ADC candidate selection
Review case studies showing how to construct and evaluate appropriate ADC candidate matrices, varying payloads, and linker elements for lead candidate selection
10:30 am Morning Break & Speed Networking
Synopsis
This is an informal session to help you connect with your peers in a relaxed atmosphere and continue forging new and beneficial relationships. You will have the opportunity to present your work, and review presentations displaying novel approaches and findings.
Exploring Stability Within ADC Linkers & Conjugations to Reduce off Target Toxicities While Ensuring Accurate Payload Release
11:30 am EZWi-Fit, A Novel Linker-Toxin Platform That Confers ADC With Improved Efficacy & Safety
Analyzing EZWi-Fit – a proprietary and novel linker-toxin platform technology, which employs potent TopIi as payload and stable cleavable linker with super hydrophilicity and minimum deconjugation by chemical modification
Evaluating ADCs derived from EZWi-Fit platform that demonstrate multiple advantages, including: (1) superior in vivo anti-tumor activity than current benchmark technology, (2) remain remarkably effective in models resistant to MMAE and Dxd ADC, (3) significantly effective in tumor models with low-level and heterogeneous target expression
Understanding how EZWi-Fit ADCs have slower clearance and greater system and tumor exposure, as well as improved HNP safety in comparison with current benchmark technology
12:00 pm Exploring Novel Linker Chemistries to Improve the Therapeutic Index
Synopsis
Discover stable bioconjugation approaches for increased ADC stability
Review tumor selective linker designs to improve the therapeutic index of ADCs
Explore the relationship between linker type and toxicity profile
12:30 pm Talk Reserved for Paul Davis
1:00 pm Networking Lunch
Addressing the Never-Ending Battle of Cleavable vs Non-Cleavable Linkers to Select the Most Appropriate One for Your ADC
2:00 pm Roundtable Discussion – Is a Linker That is Too Stable a Problem & How Do We Overcome That?
Assessing the challenges that come with a “too stable” linker
2:30 pm Exploring Click-Cleavable ADCs to Better Understand Their Applications & Potential Limitations
Marc RobillardChief Executive Officer & Founder, Tagworks Pharmaceuticals
Synopsis
Understanding limitations of current ADC linkers
Exploring the principle and design of click-cleavable ADC linkers
Targeting scope expansion and potential for improved efficacy and safety offered by click-cleavable ADCs
3:00 pm Understanding How to Tune the Cleavage Rate of Linkers to Increase Specificity Towards Tumor Microenvironments
James ItaliaVP of Commercial Development, University Health Network Canada
Synopsis
Exploring the need to tune cleavage rate
Assessing how tumor microenvironments factor into cleavage rate
Tuning cleavage rate for specific tumor microenvironments
3:30 pm Chair’s Closing Remarks
3:35 pm Scientific Poster Session
Synopsis
This is an informal session to help you connect with your peers in a relaxed atmosphere and discuss novel linker & conjugation technologies and their challenges. You will have the opportunity to present your work, and review presentations displaying novel approaches and findings.
JOIN OUR TEAM
We are always looking for ambitious people to join our team. You'll have opportunities to learn quickly, advance your career, and to meaningfully impact our customers and our business.
ABOUT US
Hanson Wade specializes in scientific research across a comprehensive range of distinctive R&D areas. We deliver insight and connections to facilitate safe and effective drug development for more personalized and targeted patient populations.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
SPL Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
(20min delay)
